Publication: Randomized, double-blind, placebo-controlled clinical trial on the usefulness of probiotic Lactobacillus reuteri in bismuth-containing quadruple eradication therapy for infection with Helicobacter pylori.
No Thumbnail Available
Identifiers
Date
2022
Authors
Moreno Márquez, Carolina
Fernández Álvarez, Paula
Valdés Delgado, Teresa
Castro Laria, Luisa
Argüelles Arias, Federico
Caunedo Álvarez, Ángel
Gómez Rodríguez, Blas José
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
the primary goal of this study was to compare gastrointestinal symptom reduction in patients on bismuth-containing quadruple eradication therapy supplemented with Lactobacillus reuteri strains (DSM 17938 and ATCC PTA 6475) or placebo. this was a randomized, double-blind, parallel-arm, placebo-controlled clinical trial. Patients received a first-line eradication regimen based on bismuth subcitrate potassium, metronidazole, tetracycline hydrochloride (three-in-one capsules) and omeprazole 40 mg twice a day for ten days, plus a probiotic or placebo tablet for 30 days. During follow-up, gastrointestinal symptoms were assessed using an evaluation scale (GSRS), and adverse events were collected at 0, 14, 28 and 56 days. a total of 80 patients were included from February 2018 to May 2019 at a single site. Eradication therapy was effective in 85 % of patients, with no differences between treatment arms. In the group receiving the probiotic, abdominal pain decreased in 42 % of patients, compared with 19 % in the control group (OR: 0.27; CI, 0.13-0.58; p
Description
MeSH Terms
Abdominal Pain
Anti-Bacterial Agents
Bismuth
Drug Therapy, Combination
Helicobacter Infections
Helicobacter pylori
Humans
Limosilactobacillus reuteri
Metronidazole
Probiotics
Treatment Outcome
Anti-Bacterial Agents
Bismuth
Drug Therapy, Combination
Helicobacter Infections
Helicobacter pylori
Humans
Limosilactobacillus reuteri
Metronidazole
Probiotics
Treatment Outcome